| Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma NH Chakiryan, DD Jiang, KA Gillis, E Green, A Hajiran, L Hugar, L Zemp, ... JAMA Network Open 4 (5), e2111329-e2111329, 2021 | 35 | 2021 |
| Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response A Hajiran, N Chakiryan, AM Aydin, L Zemp, J Nguyen, JM Laborde, ... Clinical & Experimental Immunology 204 (1), 96-106, 2021 | 31 | 2021 |
| Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy A Hajiran, M Azizi, AM Aydin, L Zemp, CC Peyton, J Dhillon, S Nealon, ... The Journal of urology 205 (1), 100-108, 2021 | 31 | 2021 |
| Perinephric hematoma size is independently associated with the need for urological intervention in multisystem blunt renal trauma L Zemp, U Mann, KF Rourke The Journal of urology 199 (5), 1283-1288, 2018 | 31 | 2018 |
| Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer NH Chakiryan, DD Jiang, KA Gillis, E Green, A Hajiran, L Hugar, L Zemp, ... The Journal of Urology 206 (4), 924-932, 2021 | 25 | 2021 |
| The 12-CK score: global measurement of tertiary lymphoid structures R Li, A Berglund, L Zemp, J Dhillon, R Putney, Y Kim, RK Jain, GD Grass, ... Frontiers in Immunology 12, 694079, 2021 | 25 | 2021 |
| Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma NH Chakiryan, GJ Kimmel, Y Kim, A Hajiran, AM Aydin, L Zemp, ... PloS one 16 (4), e0245415, 2021 | 24 | 2021 |
| Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals DD Shapiro, JA Karam, L Zemp, VA Master, WJ Sexton, A Ghasemzadeh, ... European Urology Open Science 50, 43-46, 2023 | 22 | 2023 |
| Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma NH Chakiryan, LR Gore, RR Reich, RL Dunn, DD Jiang, KA Gillis, ... JAMA Network Open 5 (5), e2212347-e2212347, 2022 | 21 | 2022 |
| Improved artificial urinary sphincter outcomes using a transcorporal cuff placement in patients with a “fragile urethra” E Redmond, S Tong, L Zemp, N Hoy, KF Rourke Canadian Urological Association Journal 14 (12), E621, 2020 | 19 | 2020 |
| Contemporary management of renal trauma in Canada: a 10-year experience at a level 1 trauma centre U Mann, L Zemp, KF Rourke Canadian Urological Association Journal 13 (6), E177, 2019 | 18 | 2019 |
| Correlating immune cell infiltration patterns with recurrent somatic mutations in advanced clear cell renal cell carcinoma NH Chakiryan, A Hajiran, Y Kim, AM Aydin, L Zemp, E Katende, J Nguyen, ... European urology focus 8 (3), 784-793, 2022 | 16 | 2022 |
| Geospatial cellular distribution of cancer-associated fibroblasts significantly impacts clinical outcomes in metastatic clear cell renal cell carcinoma NH Chakiryan, GJ Kimmel, Y Kim, JO Johnson, N Clark, A Hajiran, ... Cancers 13 (15), 3743, 2021 | 16 | 2021 |
| The selection for cytoreductive nephrectomy (SCREEN) score: improving surgical risk stratification by integrating common radiographic features EJ Abel, VA Master, PE Spiess, JD Raman, DD Shapiro, WJ Sexton, ... European Urology Oncology 7 (2), 266-274, 2024 | 15 | 2024 |
| Contemporary management of early stage testicular seminoma AM Aydin, L Zemp, SK Cheriyan, WJ Sexton, PAS Johnstone Translational andrology and urology 9 (Suppl 1), S36, 2020 | 15 | 2020 |
| Structural basis for α-conotoxin potency and selectivity M Turner, S Eidemiller, B Martin, A Narver, J Marshall, L Zemp, KA Cornell, ... Bioorganic & medicinal chemistry 17 (16), 5894-5899, 2009 | 14 | 2009 |
| Preoperative pad usage is independently associated with failure of non-adjustable male trans-obturator slings in otherwise well-selected patients L Zemp, S Tong, N Hoy, KF Rourke Canadian Urological Association Journal 13 (4), 120, 2018 | 10 | 2018 |
| Dissecting outcomes: should cytoreductive nephrectomy be performed for patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation? JJ Adashek, Y Zhang, WP Skelton IV, A Bilotta, J Chahoud, L Zemp, J Li, ... Frontiers in Oncology 10, 627025, 2021 | 8 | 2021 |
| Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity A Hajiran, L Zemp, AM Aydin, SK Cheryian, JM Pow-Sang, J Chahoud, ... Urologic Oncology: Seminars and Original Investigations 39 (1), 72. e1-72. e5, 2021 | 6 | 2021 |
| Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer AM Aydin, SK Cheriyan, R Reich, A Hajiran, CC Peyton, L Zemp, A Yu, ... Urologic Oncology: Seminars and Original Investigations 40 (10), 453. e19 …, 2022 | 5 | 2022 |
Scott M GilbertH. Lee Moffitt Cancer Center & Research Institute在 umich.edu 的电子邮件经过验证
